⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PTGX News
Protagonist Therapeutics, Inc
Phrontline Biopharma Presents Preclinical Data for TJ106, a Biparatopic HER2 Dual-Payload ADC, at American Association for Cancer Research Annual Meeting 2026
prnewswire.com
PTGX
Paytronix Customer Conference Draws Top Brands in Hospitality to PX|NXT
globenewswire.com
PTGX
Centri Announces Panel Topics and Featured Programming for Second Annual Capital Conference at Nasdaq on April 14
accessnewswire.com
NDAQ
DFIN
PTGX
STRL
TNDM
AXSM
CSTL
CYTK
GILD
INSM
KODK
NBIX
OCGN
REGN
SRPT
VRTX
XBIT
AMZN
GOOGL
MSFT
NVDA
IBM
ORGN
BWEN
CCJ
EXC
NEE
SO
UTL
XOM
BALY
OXY
PBF
CHRD
AX
BAC
MAXN
PHIO
KZR
SMX
DUOT
COIN
EHTH
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
accessnewswire.com
PTGX
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
accessnewswire.com
PTGX
JNJ
Avalyn Appoints Biopharmaceutical Industry Leader Kate Haviland to Board of Directors
globenewswire.com
PTGX
SNY
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
businesswire.com
TAK
PTGX
Santhera Announces Proposed Inclusion and Reimbursement of AGAMREE® (Vamorolone) within Spain’s National Health System for the Treatment of Duchenne Muscular Dystrophy
globenewswire.com
CRSP
REGN
PTGX
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
accessnewswire.com
PTGX
Form 8-K
sec.gov
PTGX